Education
About Us
Working with TipRanks
Follow Us
Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
RESEARCH TOOLSreports
Total Valuation
Marksans Pharma Limited has a market cap or net worth of ₹78.49B. The enterprise value is ₹97.16B.
Market Cap₹78.49B
Enterprise Value₹97.16B
Share Statistics
Marksans Pharma Limited has 453,163,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding453,163,760
Owned by Insiders―
Owned by Institutions0.13%
Financial Efficiency
Marksans Pharma Limited’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 30.38%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)30.38%
Return on Capital Employed (ROCE)0.41
Revenue Per Employee22.99M
Profits Per Employee3.34M
Employee Count1,141
Asset Turnover0.81
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Marksans Pharma Limited is 22.4. Marksans Pharma Limited’s PEG ratio is ―.
PE Ratio22.4
PS Ratio―
PB Ratio―
Price to Fair Value4.08
Price to FCF―
Price to Operating Cash Flow0.00
PEG Ratio―
Income Statement
In the last 12 months, Marksans Pharma Limited had revenue of 26.23B and earned 3.81B in profits. Earnings per share was 8.40.
Revenue26.23B
Gross Profit14.79B
Operating Income11.29B
Pretax Income5.04B
Net Income3.81B
EBITDA5.29B
Earnings Per Share (EPS)8.40
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Marksans Pharma Limited pays an annual dividend of ₹0.8, resulting in a dividend yield of 0.47%
Dividend Per Share₹0.8
Dividend Yield0.47%
Payout Ratio17.72%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-28.76%
50-Day Moving Average228.63
200-Day Moving Average248.73
Relative Strength Index (RSI)17.52
Average Volume (3m)568.93K
Important Dates
Marksans Pharma Limited upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend DateAug 01, 2025
Financial Position
Marksans Pharma Limited as a current ratio of 4.62, with Debt / Equity ratio of 13.05%
Current Ratio4.62
Quick Ratio2.85
Debt to Market Cap<0.01
Net Debt to EBITDA-0.72
Interest Coverage Ratio96.81
Taxes
In the past 12 months, Marksans Pharma Limited has paid 1.21B in taxes.
Income Tax1.21B
Effective Tax Rate0.24
Enterprise Valuation
Marksans Pharma Limited EV to EBITDA ratio is 18.30, with an EV/FCF ratio of 286.69.
EV to Sales3.69
EV to EBITDA18.30
EV to Free Cash Flow286.69
EV to Operating Cash Flow46.81
Balance Sheet
Marksans Pharma Limited has ₹7.05B in cash and marketable securities with ₹3.22B in debt, giving a net cash position of -₹3.83B billion.
Cash & Marketable Securities₹7.05B
Total Debt₹3.22B
Net Cash-₹3.83B
Net Cash Per Share-₹8.45
Tangible Book Value Per Share₹52.44
Margins
Gross margin is 56.87%, with operating margin of 43.04%, and net profit margin of 14.51%.
Gross Margin56.87%
Operating Margin43.04%
Pretax Margin19.21%
Net Profit Margin14.51%
EBITDA Margin20.16%
EBIT Margin16.98%
Analyst Forecast
The average price target for Marksans Pharma Limited is ₹271.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹271.00
Price Target Upside60.12% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast16.94%
EPS Growth Forecast4.90%